1327238--5/18/2010--CYPLASIN_BIOMEDICAL

related topics

{stock, price, share}

{acquisition, growth, future}

{property, intellectual, protect}

{product, candidate, development}

{product, liability, claim}

{product, market, service}

{control, financial, internal}

{regulation, change, law}

{regulation, government, change}

We have had negative cash flows from operations since inception. We will require significant additional financing, the availability of which cannot be assured, and if our company is unable to obtain such financing, our business may fail. We have a history of losses and nominal operating results, which raise substantial doubt about our ability to continue as a going concern. Our inability to complete our product development activities successfully may severely limit our ability to operate and finance operations. We may lose our competitiveness if we are not able to protect our proprietary technology and intellectual property rights against infringement, and any related litigation may be time-consuming and costly Our company may become subject to intellectual property litigation which may harm our business. If our company commercializes or tests our technology, our company will be subject to potential product liability claims which may affect our earnings and financial condition. If we fail to effectively manage the growth of our company and the commercialization or licensing of our technology, our future business results could be harmed and our managerial and operational resources may be strained. Failure to obtain and maintain required regulatory approvals will severely limit our ability to commercialize our technology. Even if we obtain regulatory approval to commercialize our products, lack of commercial acceptance may impair our business. If we do not keep pace with our competitors, technological advancements and market changes, our technology may become obsolete and our business may suffer. Our business is subject to comprehensive government regulation and any change in such regulation may have a material adverse effect on our company. A decline in the price of our common stock could affect our ability to raise further working capital and adversely impact our ability to continue operations Trading of our stock may be restricted by the Securities Exchange Commission's penny stock regulations, which may limit a stockholder's ability to buy and sell our stock. The Financial Industry Regulatory Authority, or FINRA, has adopted sales practice requirements which may also limit a stockholder's ability to buy and sell our stock. Our common stock is illiquid and the price of our common stock may be negatively impacted by factors which are unrelated to our operations

Full 10-K form ▸

1327238--5/18/2010--CYPLASIN_BIOMEDICAL_LTD.